Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

AGIOS PH. Form 4 February 23	ARMACEUTICA	LS INC									
	FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL		
-	Washington, D.C. 20549							N OMB Number:	3235-0287		
if no lor subject Section Form 4 Form 5 obligation may cor	obligations may continue.Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Estimated burden hou response	urs per		
(Print or Type	Responses)										
Biller Scott S			2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]					5. Relationship of Reporting Person(s) to IssuerC (Check all applicable)			
(1				3. Date of Earliest Transaction (Month/Day/Year) 02/21/2017				Director 10% Owner X Officer (give title Other (specify below) below) Chief Scientific Officer			
				. If Amendment, Date Original iled(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
CAMBRID	OGE, MA 02139							Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Secur	rities A	cquired, Disposed (of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	rity (Month/Day/Year) Execution		Date, if Transactio Code		4. Securities nAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities benef	ficially own	ned di	rectly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 2 4. 7. Title and Amount of 8 Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Γ (Instr. 3 and 4) Security or Exercise any Code Securities (Month/Day/Year) Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Code V (A) (D) Date Expiration Title Amount Exercisable Date or Number of Shares Stock option Common \$ 50.4 02/21/2017 47,600 (1) 02/20/2027 47,600 Α stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** Other Director 10% Owner Officer **Biller Scott** C/O AGIOS PHARMACEUTICALS, INC. Chief Scientific Officer **88 SIDNEY STREET** CAMBRIDGE, MA 02139 **Signatures** /s/ Andrew Hirsch, as attorney-in-fact for Scott 02/23/2017 Biller **Signature of Reporting Person Date **Explanation of Responses:**

Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, (1)2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S

(